Zymeworks (NASDAQ: ZYME) swings to a profit on a $250 million Jazz milestone

What happened

Zymeworks Inc. (NASDAQ: ZYME) swung to a third-quarter profit on a $250 million milestone from Jazz Pharmaceuticals tied to U.S. approval of Ziihera.

Net income was $173.7 million in the quarter ended Sept. 30, against a net loss of $19.6 million a year earlier. Diluted earnings per share were $2.28, versus a loss of $0.26. Revenue reached $256.5 million, up from $27.6 million. The filing attributes the rise primarily to the Jazz milestone.

Zymeworks raised 2026 revenue guidance to $337 million to $351 million, from $278 million to $292 million. Adjusted EBITDA guidance now runs from $176 million to $190 million, up from $114 million to $128 million. Both ranges exclude the effect of any future transactions.

The company also closed its Theravance Biopharma acquisition on Sept. 23. The unit added about $1.5 million of revenue in the quarter, covering seven days of ownership.

Key numbers

Metric	Latest	Change	Source
Total revenue, Q3 2026	$256.5 million	from $27.6 million, +$228.9 million	Calculated from SEC 8-K
Net income (loss), Q3 2026	$173.7 million	from -$19.6 million, +$193.3 million	Calculated from SEC 8-K
Diluted EPS, Q3 2026	$2.28	from -$0.26, +$2.54	Calculated from SEC 8-K
2026 revenue guidance (prior range $278 million to $292 million)	$337 million to $351 million	+$59 million at each end	SEC 8-K Exhibit 99.1
Net margin, Q3 2026	67.7%	from -71.0%, +138.7 percentage points	Calculated from SEC 8-K
Cash and short-term marketable securities (Sept. 30, 2026 versus Dec. 31, 2025)	$100.5 million	from $228.8 million	SEC 8-K Exhibit 99.1

Read more: Zymeworks (ZYME) company research

Why it matters

The quarter shows the partner-funded model paying out, though in one lump. OptimistFi has argued that ZYME works if its licensed assets turn scientific optionality into repeatable partner-funded milestones before cash burn forces dilution. Revenue rose by $228.9 million year over year, and the one-time Jazz payment drove most of it.

More milestones are possible but not banked. Zymeworks is eligible for up to $190 million in further ex-U.S. regulatory milestones on Ziihera from Jazz and BeOne Medicines. It could also earn up to $718 million in additional Roche milestones on ZW209.

The balance sheet carries the caveat. Cash, cash equivalents and short-term marketable securities were $100.5 million on Sept. 30, down from $228.8 million at Dec. 31, 2025. Long-term liabilities rose to $756.7 million from $35.7 million. Zymeworks says it accessed $600 million of non-dilutive financing in 2026 and has no current plans for additional equity issuances.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

The Roche collaboration on ZW209 awaits the end of the Hart-Scott-Rodino waiting period, expected in the fourth quarter of 2026. The raised guidance depends on it. Clearance on schedule would support the new ranges, while a delay would leave them open.

Zymeworks plans to host an R&D Day in New York on Feb. 11, 2027.

More from OptimistFi

• ZYME stock: research and coverage of Zymeworks
• Stock research on every company OptimistFi covers

From OptimistFi Perps